Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 7/2011

01-07-2011 | Original Research Article

Iron-Chelating Therapies in a Transfusion-Dependent Thalassaemia Population in Thailand

A Cost-Effectiveness Study

Authors: Nantasit Luangasanatip, Dr Nathorn Chaiyakunapruk, Nilawan Upakdee, Peerapon Wong

Published in: Clinical Drug Investigation | Issue 7/2011

Login to get access

Abstract

Background and Objective: β-Thalassaemia is a major public health problem in Thailand. Use of appropriate iron-chelating agents could prevent thalassaemia-related complications, which are costly to the healthcare system. This study aimed to evaluate the cost effectiveness of deferoxamine (DFO), deferiprone (DFP) and deferasirox (DFX) in Thai transfusion-dependent β-thalassaemia patients from the societal perspective.
Methods: A Markov model was used to project the life-time costs and outcomes represented as quality-adjusted life-years (QALYs). Data on the clinical efficacy and safety of all therapeutic options were obtained from a systematic review and clinical trials. Transition probabilities were derived from published studies. Costs were obtained from the Thai Drug and Medical Supply Information Center, Thai national reimbursement rate information and other Thai literature sources. A discount rate of 3% was used. Incremental cost-effectiveness ratios (ICERs) were presented as year 2009 values. A base-case analysis was performed for thalassaemia patients requiring regular blood transfusion therapy, while a separate analysis was performed for patients requiring low (i.e. symptom-dependent, less frequent) blood transfusion therapy. A series of sensitivity analysis and cost-effectiveness acceptability curves were constructed.
Results: Compared with DFO, using DFP was dominant with lifetime cost savings of $US91 117. Comparing DFX with DFO, the incremental cost was $US522 863 and incremental QALY was 5.77 with an ICER of $US90 648 per QALY. When compared with DFP, the ICER of DFX was $US106445 per QALY. A cost-effectiveness analysis curve showed the probability of DFX being cost effective was 0% when compared with either DFO or DFP, based on the cost-effectiveness cut-off value of $US2902 per QALY. When compared with DFP, DFX was cost effective only if the DFX cost was as low as $US1.68 per 250mg tablet. The results of the analysis in patients requiring low blood transfusion therapy were not different from those of the base-case analysis.
Conclusions: Our findings suggest that using DFP is cost saving when compared with conventional therapy, while using DFX is not cost effective compared with either DFO or DFP in Thai patients with transfusiondependent b-thalassaemia. Policy-makers and clinicians may consider using such information in their decision-making process in Thailand.
Literature
1.
Akinyanju O, Angastiniotis M, Brozovic M, et al., editors. Guidelines for the control of haemoglobin disorders. The 6th Annual Meeting of the WHO Working Group on Haemoglobinopathies; 1989; Cagliari, Sardinia; 8–9 April
2.
Eleftherioue A. About thalassaemia. Nicosia, Cyprus: Thalassaemia International Federation, 2003
3.
Christianson A, Modell B. Medical genetics in developing countries. Annu Rev Genomics Hum Genet 2004; 5: 219–65PubMedCrossRef
4.
Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001; 79(8): 704–12PubMed
5.
Fucharoen S, Winichagoon P, Siritanaratkul N, et al. Alpha-and beta-thalassemia in Thailand. Ann N Y Acad Sci 1998; 850: 412–4PubMedCrossRef
6.
7.
Olivieri NF, Britten GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739–61PubMed
8.
Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001: 47-61
9.
Ladis V, Chouliaras G, Berdousi H, et al. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci 2005; 1054: 445–50PubMedCrossRef
10.
Telfer P, Coen P, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus: trends and risk factors over the period 1980–2004. Haematologica 2006; 91: 1187–92PubMed
11.
Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355(9220): 2051–2PubMedCrossRef
12.
Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332(14): 918–22PubMedCrossRef
13.
Borgna-Pignatti C, Capellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Sci 2005; 1054: 40–7CrossRef
14.
Roberts DJ, Brunskill SJ, Doree C, et al. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2007; Jul 18; (3): CD004839
15.
Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455–62PubMedCrossRef
16.
Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873–80PubMed
17.
Maggio A, D’Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassaemia major: a randomised clinical trial. Blood Cells Mol Dis 2002; 28(2): 196–208PubMedCrossRef
18.
Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738–44PubMedCrossRef
19.
Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian J Pediatr 2004; 41: 21–7
20.
21.
22.
23.
Thai Working Group on Health Technology Assessment Guidelines in Thailand. Thai Health Technology Assessment Guidelines. J Med Assoc Thai 2008; 91Suppl. 2: S1–88
24.
25.
Delea TE, Sofrygin O, Thomas SK, et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients. Pharmacoeconomics 2007; 25(4): 330–42CrossRef
26.
27.
Chouliaras G, Yiannoutsos T, Berdoukas V, et al. Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek Unit. Eur J Haematol 2009; 82: 381–7PubMedCrossRef
28.
Drummond MF, Mark JS, George WT, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
29.
Awat Chaolilitkul. Food and nutrition status report of Thai population. 4th ed. Nontaburi: Nutrition Division, Department of Public Health, 1995
30.
31.
Ministry of Public Health (MOPH). Reimbursement rate year 2007, Thailand
32.
UDOM medical Equipment Co. Ltd, Bangkok. Official distributor of Infusion Pump; INFUSA TS™
33.
Government 12-file standard data set of hospital database 2003–2007, Centre for Health Equity Monitoring (CHEM), Naresuan University, Phitsanulok, Thailand, 2008
34.
Kasemsap W, Jeungsaman P, Sakthong P, et al. The assessment of peritoneal renal dialysis service in late state of chronic renal failure patients under the Universal Coverage of Health Care Scheme: National Health Security Office (NHSO), Thailand, 2009
35.
Chirakup S, Chaiyakunapruk N, Chaikledkaew U, et al. Costeffectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. Value Health 2008; 11Suppl. 1: S43–51PubMedCrossRef
36.
Riewpaiboon A, Nuchprayoon I, Torcharus K, et al. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children. BMC Res Notes 2010; 3(1): 29PubMedCrossRef
37.
38.
Osborne RH, Lourenco R, Dalton A, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health 2007; 10(6): 451–6PubMedCrossRef
39.
Cappellini MD, Cohen A, Eleftheriou A, et al. Guidelines for the clinical management of thalassaemia. 2nd rev. ed. Nicosia: Thalassaemia International Federation, 2008
40.
Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Poster presented at the American Society of Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13(2): 89–102PubMedCrossRef
41.
Pansatienkul B, editors. Clinical practice guidelines for diagnosis and management of thalassemia syndromes. Department of Medical Services, Ministry of Public Health (Thailand), 2006
42.
Pootrakul S, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003; 122(2): 305–10PubMedCrossRef
43.
WHO Commission on Macroeconomic and Health. Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization, 2001
44.
Karnon J, Tolley K, Oyee J, et al. Cost utility analysis of deferasirox (Exjade®) versus deferoxamine (Desferal) for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin 2008; 24(6): 1609–21PubMedCrossRef
45.
46.
Nuijten MJ, Rutten F. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. Pharmacoeconomics 2002; 20(12): 855–67PubMedCrossRef
47.
Anthony TN, Health K, Stuart H, et al. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group. Pharmacoeconomics 2009; 27(6): 439–50CrossRef
48.
Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360(9332): 516–20PubMedCrossRef
49.
Ngarmsiriudom B. Prevention and control of thalassaemia in Thailand under the national total health care coverage policy. 8th National Thalassemia Conference, Khon Kaen, August 8–9; 2003
50.
Metadata
Title
Iron-Chelating Therapies in a Transfusion-Dependent Thalassaemia Population in Thailand
A Cost-Effectiveness Study
Authors
Nantasit Luangasanatip
Dr Nathorn Chaiyakunapruk
Nilawan Upakdee
Peerapon Wong
Publication date
01-07-2011
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 7/2011
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/11587120-000000000-00000

Other articles of this Issue 7/2011

Clinical Drug Investigation 7/2011 Go to the issue

Original Research Article

Identifying Amnestic Mild Cognitive Impairment in Primary Care

Original Research Article

Administration of CREON® Pancrelipase Pellets via Gastrostomy Tube is Feasible with No Loss of Gastric Resistance or Lipase Activity

Original Research Article

Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy

Review Article

Combination Delapril/Manidipine as Antihypertensive Therapy in High-Risk Patients

Review Article

Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder